AN-DTPA® Kit for the Preparation of
Technetium Tc 99m Pentetate Injection
Diagnostic For Intravenous Use
AN-DTPA® Kit for the Preparation of Technetium Tc 99m Pentetate Injection is a multidose reaction vial which contains the sterile, non-pyrogenic, non-radioactive ingredients necessary to produce Technetium Tc 99m Pentetate Injection for diagnostic use by intravenous injection. Each 10 mL reaction vial contains 20.6 mg pentetate calcium trisodium, 0.15 mg minimum stannous tin as stannous chloride dihydrate and 0.30 mg maximum total tin as stannous chloride dihydrate in lyophilized form and sealed under nitrogen. The pH is adjusted to 3.9-4.1 with sodium hydroxide and/or hydrochloric acid prior to lyophilization. No bacteriostatic preservative is present. The active agent is a Technetium Tc 99m complex of pentetate calcium trisodium.
AN-DTPA (Pentetate Calcium Trisodium) is indicated for the following:
Technetium Tc 99m Pentetate Injection may be used to perform kidney imaging, brain imaging, to assess renal perfusion and to estimate glomerular filtration rate.
Published Studies Related to AN-Dtpa (Technetium Tc 99m Pentetate)
Effect of hydroxyurea treatment on renal function parameters: results from the
multi-center placebo-controlled BABY HUG clinical trial for infants with sickle
cell anemia. 
CONCLUSION: Treatment with hydroxyurea for 24 months did not influence GFR in
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). [2011.05.14]
BACKGROUND: Sickle-cell anaemia is associated with substantial morbidity from acute complications and organ dysfunction beginning in the first year of life. Hydroxycarbamide substantially reduces episodes of pain and acute chest syndrome, admissions to hospital, and transfusions in adults with sickle-cell anaemia. We assessed the effect of hydroxycarbamide therapy on organ dysfunction and clinical complications, and examined laboratory findings and toxic effects... INTERPRETATION: On the basis of the safety and efficacy data from this trial, hydroxycarbamide can now be considered for all very young children with sickle-cell anaemia. FUNDING: The US National Heart, Lung, and Blood Institute; and the National Institute of Child Health and Human Development. Copyright (c) 2011 Elsevier Ltd. All rights reserved.
A randomized crossover study of the effects of glutamine and lipid on the gastric emptying time of a preoperative carbohydrate drink. [2011.04]
BACKGROUND & AIMS: Supplementing preoperative carbohydrate drinks with glutamine may lead to benefits in addition to reducing insulin resistance, but amino acids may delay gastric emptying (GE). The effects of supplementing a preoperative carbohydrate drink (CCD) with glutamine or lipid on GE were studied... CONCLUSIONS: Glutamine and lipid supplementation did not prolong the GE of CCD but did 'blunt' postprandial glucose and insulin responses, independent of GLP-1 concentrations. Registered under ClinicalTrials.gov Identifier no. NCT00943020. Copyright (c) 2010 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.
In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets. [2010.10.01]
The purpose of this study was to evaluate and compare the in-vitro and in-vivo erosion profiles of two tablet formulations primarily consisting of hydroxypropylmethylcellulose (HPMC) and lactose. HPMC was used at concentrations below and above the reported values for polymer percolation threshold in controlled release matrix formulations: 20 and 40% (w/w) HPMC.
Assessment of levetiracetam bioavailability from targeted sites in the human intestine using remotely activated capsules and gamma scintigraphy: Open-label, single-dose, randomized, four-way crossover study in healthy male volunteers. [2010.09]
BACKGROUND: Levetiracetam is a broad-spectrum antiepileptic drug that binds to synaptic vesicle protein SV2A. Levetiracetam is indicated in the adjunctive treatment of partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures. It is also approved in Europe as monotherapy for newly diagnosed partial-onset seizures. A Phase I clinical pharmacology trial was conducted during preregistration clinical development to better understand the regional gastrointestinal (GI) absorption of levetiracetam. OBJECTIVE: This study evaluated the relative bioavailability of levetiracetam in various regions of the GI tract using a noninvasive, remote-controlled capsule device providing targeted drug delivery, relative to that after oral administration, and explored the drug's absorption characteristics in healthy volunteers... CONCLUSION: After delivery in the proximal small bowel, distal small bowel, or ascending colon, the systemic bioavailability of levetiracetam (AUC), but not C(max) and T(max), appeared comparable to that after oral administration and thus appeared site independent in this small group of healthy fasting men. Copyright A(c) 2010 Excerpta Medica Inc. All rights reserved.
Clinical Trials Related to AN-Dtpa (Technetium Tc 99m Pentetate)
SPECT/CT in Measuring Lung Function in Patients With Lung Cancer Undergoing Radiation Therapy [Recruiting]
This pilot clinical trial studies single photon emission computed tomography
(SPECT)/computed tomography (CT) in measuring lung function in patients with lung cancer
undergoing radiation therapy. Diagnostic procedures that measure lung function may help
doctors find healthy lung tissue and allow them to plan better treatment.
Determination of Kidney Function [Recruiting]
Much more about kidney disorders can be learned by determining kidney function. This
research proposes to study the kidneys function by several parameters known as glomerular
filtration rate (GFR), Renal Plasma Flow (RPF), and Glomerular Capillary Wall
The study will select patients suffering from different types of kidney diseases. These
patients will be selected based on the presence of significant amounts of protein in their
Standard blood and urine tests are often unable to provide completely accurate information
about the kidney. In order for researchers to have a more accurate idea of kidney function,
they will use alternative tests. Test materials (para aminohippurate and inulin) will be
injected into patients veins that provides information based on their filtration through the
Tenofovir Renal Toxicity and Glomerular Filtration Rate (GFR) Validation [Recruiting]
Cardiopulmonary Function Assessment and NO-Based Therapies for Patients With Hemolysis-Associated Pulmonary Hypertension [Recruiting]
This study will evaluate new treatments for people who have pulmonary hypertension, or high
blood pressure in the lungs, caused by sickle cell anemia or thalassemia.
Patients ages 18 and older with a diagnosis of sickle cell disease or thalassemia, who have
mild to severe pulmonary hypertension, and who are not pregnant or breastfeeding may be
eligible for this study. There are three stages in the study, with up to 200 participants in
the screening. Patients will undergo pulmonary function tests, including those for asthma
and measurement of oxygen levels in the arterial blood. They will have a chest X-ray,
computed tomography (CT) scan of the lungs, ventilation perfusion lung scan to look for
blood clots, echocardiogram, test to measure how far patients can walk in 6 minutes,
nighttime oxygen measurement done while asleep, blood collection, magnetic resonance imaging
(MRI) scan of the heart, and exercise test. About 3 to 4 days are needed for the tests, all
of which can be done while patients are outpatients, except for the sleep study. For the CT
scan, patients lie on a table while an X-ray beam takes images of the lungs and heart. The
lung scan involves breathing of a small amount of a radioactive aerosol called Tc99m DTPA
while pictures are taken of the lungs from various angles. Then an injection of albumin, a
protein with a small amount of radioactivity, will be given, and more lung pictures will be
taken. For the MRI scan, patients lie on a table that slides into a machine. A medication
called gadolinium will be injected, to help improve images made through the scan. After the
tests, patients will be admitted to the Clinical Center for 1 day. A small plastic catheter,
or tube, will be placed in the vein of an arm. A longer catheter will go into a deeper vein
(neck or leg), and a pulmonary artery catheter will be inserted to measure blood pressure in
the blood vessels. Doctors will guide the catheter into the lung artery. Patients will be
asked to pedal on a stationary bicycle while heart and lung pressure is measured. If
pulmonary hypertension is present, patients will proceed to the second stage (up to 50
participants). While the catheter is still in place, patients will wear a face mask and
breathe nitric oxide (NO) for 20 minutes. They will take 50 mg of sildenafil by mouth, and
pressure in the heart and lungs will be monitored for about 4 hours. They will again receive
NO for another 20 minutes. Blood samples will be taken, and the heart rhythm and pressure in
the lungs will be monitored. Sildenafil can cause headache, flushing, and indigestion. Side
effects of the lung scan involve allergic reactions to DTPA and albumin. Patients with an
allergy to eggs should not have that test.
Up to 25 patients can enter the third stage. They will breathe NO by using a tank of gas
that delivers it through tubes to the nose, for a period of 6 weeks. They will continue
taking sildenafil as previously prescribed and visit the clinic every 2 to 4 weeks for an
echocardiogram, blood tests, and 6-minute walk test. After 6 weeks, patients will have
catheterization of the heart again to measure pressure in the heart and lungs. Then NO will
be stopped, and pressure in the lungs will be checked to see if NO has helped lower the
blood pressure-and to make sure that the blood pressure does not increase when medication is
stopped. Patients whose symptoms have improved as a result of breathing NO may wish to
continue with that therapy.
Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study) [Not yet recruiting]
Renal atherosclerotic stenosis (RAS) is a prevalent cause of secondary hypertension (HT).
Since there are still uncertainties as to whether and in what patients revascularization by
means of percutaneous renal angioplasty (PTRAS) should be pursued, we designed a study
exploiting an optimized patient selection strategy and using hard experimental endpoints to
unravel these uncertainties.
Primary objective: to determine if revascularization by means of PTRAS is superior or
equivalent to optimal medical treatment for preserving glomerular filtration rate in the
ischemic kidney as assessed by 99mTcDTPA sequential renal scintiscan.
Secondary objectives: to determine if the two treatments are equivalent in lowering blood
pressure (BP), preserving overall renal function and regressing damage in the target organs
Design: prospective multicenter randomized, unblinded two-arm study.
Eligible patients will have clinical and/or radiological evidence of unilateral or bilateral
RAS, defined by stenosis of the proximal portion of the renal artery and its main
bifurcations at angioCT. Duplex scan will exclude nephroangiosclerosis as the latter could
bias the assessment of the outcome of revascularization.
Inclusion criteria. RAS affecting the main renal artery or its major branches at angio-CT
either > 70% or, if < 70 with post-stenotic dilatation.
Renal function will be assessed with 99mTc-DTPA renal scintigraphy.
Sample size (30 patients per arm) was calculated to have a 90% power to detect a difference
in means of GFR in the vascularized (or control untreated kidney) of 7. 5 ml/min.
1. Revascularization: digital scan angiography and PTA with stenting of the renal artery
at the ostium or at truncular level, plus optimal medical therapy.
2. Medical therapy: the drug regimen that had been optimized during the run-in period.
The absolute value of GFR assessed by 99TcDTPA in the ischemic kidney will be used as
quantitative variable and compared between groups at each time point. A categorical
definition of kidney loss, defined as a GFR in the ischemic kidney of < 5 ml/min, will be
also used and the rate of achievement of such endpoint will be compared.
Duration: 5 years.
Page last updated: 2013-02-10